Duane H. Hamilton, Ph.D.
- Center for Cancer Research
- National Cancer Institute
- Bulding 10, Room 8B08
- Bethesda, MD 20892
- 240-858-3453
- Duane.Hamilton@nih.gov
RESEARCH SUMMARY
Dr. Hamilton is a Staff Scientist and Head of the Immunomodulation Group of the Center for Immuno-Oncology, NCI. This group focuses on the identification and characterization of tumor-specific neoepitopes and their use in combination therapies. This group is also involved in the genetic modification to tumor cells to identify mechanisms of action of specific immunotherapeutic agents.
Dr. Hamilton received his Ph.D. in Immunology from the University of Saskatchewan, Canada. Dr. Hamilton's research interests include cellular immunotherapy; tumor immunology; cancer vaccines. The Immunomodulation Group is working to identify and characterize tumor-specific neoepitopes and their use in combination therapies. We are also involved in the genetic modification to tumor cells to identify mechanisms of action of specific immunotherapeutic agents. This group evaluates techniques to identify tumor antigens unique to a patient’s own tumor. It is this group's belief that vaccinating patients with neoepitopes uniquely expressed by their tumor will improve the breadth of anti-tumor immunity generated by the lab's vaccine platforms, and result in greater immunological control of tumor growth.
Areas of Expertise
Research
The main goal of our research program is to identify and characterize tumor-specific antigens and neoepitopes. We are evaluating techniques to identify tumor antigens unique to a patient’s own tumor. It is our belief that vaccinating patients with neoepitopes uniquely expressed by their tumor will improve the breadth of anti-tumor immunity generated by our vaccine platforms, and result in greater immunological control of tumor growth.
Publications
Efficient tumor clearance and diversified immunity through neoepitope vaccines and combinatorial immunotherapy
Targeting estrogen receptor signaling with fulvestrant enhances immune and chemotherapy-mediated cytotoxicity of human lung cancer
WEE1 inhibition alleviates resistance to immune attack of tumor cells undergoing epithelial-mesenchymal transition
Immune targeting of tumor epithelial-mesenchymal transition via brachyury-based vaccines (Review)
An immunotherapeutic intervention against tumor progression: Targeting a driver of the epithelial-to-mesenchymal transition
Biography
Duane H. Hamilton, Ph.D.
Dr. Duane Hamilton received his Ph.D. degree in Immunology from the University of Saskatchewan, Canada, in 2007. He subsequently joined the NIH as a Postdoctoral Fellow in the (former) Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, and was appointed as a Staff Scientist in 2015. He is currently the head of the Immunomodulation Group of the Center for Immuno-Oncology's Translataionl Research area. Dr. Hamilton’s current research focuses on the identification and characterization of novel tumor-specific antigens and neoepitopes that can help the immune system to target and eliminate cancer cells.
